| abstract |
A human anti-TNFα antibody that is D2E77, or a human anti-TNFα antibody with properties equivalent to D2E7, which dissociates from human TNFα with a Kd of 1 x 10 -8 M or less and a koff dissociation rate constant of 1 x 10 -3 s -1 or less, both determined by surface plasmon resonance, and that neutralizes the cytotoxicity of human TNFα in a conventional in vitro L929 assay with an IC50 of 1 x 10 -7 M or less, for use in the treatment or relief of arthritis, in which the anti-TNFα antibody is administered at a low dose of 0.01-0.11 mg / kg, such that arthritis is treated or relieved. |